VKTXViking Therapeutics, Inc.
$28.50+12% 1Y
$28.50
$24.9752 weeks$40.87
VKTX in its own filings
Nothing in VKTX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
215
Events found in the filings · across 649 filings · the record starts in 2014
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 28, 2026
Most recent filing · Form 8-K
- Record starts
- Jun 19, 2014
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 21, 2026
- Change in certifying accountantpast_3y
- 2025-04-23
- Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares
- 2021-04-08
- SEC comment-letter activity41 occurrences
- 2025-04-21
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026Equity Offering On September 23, 2026, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC (the “Equity Representatives”), as representatives of the several underwriters named therein (the …Material agreement entered · Form 8-K
- Sep 22, 2026On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735.Other event · Form 8-K
- Jul 29, 2026Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Apr 29, 2026Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Feb 11, 2026Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update.Earnings release · press release
- Oct 22, 2025Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks